Merck & Co. Inc. (MRK)

82.95
0.87 1.06
NYSE : Health Technology
Prev Close 82.08
Open 82.10
Day Low/High 81.85 / 83.17
52 Wk Low/High 52.83 / 81.29
Volume 8.83M
Avg Volume 12.06M
Exchange NYSE
Shares Outstanding 2.58B
Market Cap 211.43B
EPS 2.30
P/E Ratio 35.00
Div & Yield 2.20 (2.45%)
Putting the Markets in Focus: Cramer's 'Mad Money' Recap (Thursday 11/15/18)

Putting the Markets in Focus: Cramer's 'Mad Money' Recap (Thursday 11/15/18)

Jim Cramer says perception is determining how stocks trade right now -- and there's a lot of negativity.

Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared To Chemotherapy In Patients With Advanced Esophageal Or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)

Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared To Chemotherapy In Patients With Advanced Esophageal Or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Phase 3 KEYNOTE-181 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy in the second-line treatment of advanced or metastatic esophageal or...

Merck Begins Rolling Submission Of Licensure Application For V920 (rVSV∆G-ZEBOV-GP) To U.S. Food And Drug Administration

Merck Begins Rolling Submission Of Licensure Application For V920 (rVSV∆G-ZEBOV-GP) To U.S. Food And Drug Administration

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it has started the submission of a rolling Biologics License Application (BLA) to the U.

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc is the #4 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Merck & Co Inc is also a top tier analyst pick among the broader S&P 500 index components, claiming the #24 spot out of 500.

The New #1 Most Shorted Dow Component: Merck

The New #1 Most Shorted Dow Component: Merck

The most recent short interest data has been released for the 10/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

FDA Accepts Regulatory Submission For LYNPARZA® (olaparib) Maintenance Therapy In Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer And Grants Priority Review

FDA Accepts Regulatory Submission For LYNPARZA® (olaparib) Maintenance Therapy In Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer And Grants Priority Review

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

FDA Approves Merck's KEYTRUDA® (pembrolizumab) For The Treatment Of Patients With Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated With Sorafenib

FDA Approves Merck's KEYTRUDA® (pembrolizumab) For The Treatment Of Patients With Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated With Sorafenib

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

Drug Stocks Climb as Investors Digest Midterm Election Results

Drug Stocks Climb as Investors Digest Midterm Election Results

A split Congress is the best-case scenario for the drug industry, several analysts said.

Early Phase 1 Data From Merck's Oncology Pipeline For Investigational Anti-LAG-3 Therapy (MK-4280) And Anti-TIGIT Therapy (MK-7684) To Be Presented At SITC's 33rd Annual Meeting

Early Phase 1 Data From Merck's Oncology Pipeline For Investigational Anti-LAG-3 Therapy (MK-4280) And Anti-TIGIT Therapy (MK-7684) To Be Presented At SITC's 33rd Annual Meeting

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentations of preliminary safety and efficacy data from Phase 1/2 dose finding studies for the company's investigational anti-LAG-3 therapy (MK-4280) and...

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.

What Is the Dow Jones Industrial Average?

What Is the Dow Jones Industrial Average?

The Dow Jones Industrial Average is a price-weighted average of 30 large American publicly traded companies on the stock market.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Dow Closes 400 Points Higher as Wall Street Rebounds on Earnings

Dow Closes 400 Points Higher as Wall Street Rebounds on Earnings

The Dow Jones Industrial Average snaps back solidly Thursday after plunging more than 600 points in the previous session.

Global Stock Sell-Off Wipes Trillions From Markets; US Futures Look To Rebound

Global Stock Sell-Off Wipes Trillions From Markets; US Futures Look To Rebound

Global stocks were awash with red in overnight trading Thursday, loping billions in value from equity markets around Asia following last night's late-trading collapse on Wall Street which has erased year-to-date gains for benchmarks around the world amid concerns over weakening U.S. earnings growth, rising geo-political tensions and the unknown outcome of trade disputes between Washington and its major economic partners.

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

It becomes difficult for me to tell you where to run in these markets...

Merck Announces Increased Fourth-Quarter Dividend And $10 Billion Share Repurchase Authorization

Merck Announces Increased Fourth-Quarter Dividend And $10 Billion Share Repurchase Authorization

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that its Board of Directors has approved a 15 percent increase to the company's quarterly dividend, raising it to $0.

Financial Highlights Package

Financial Highlights Package

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2018.

Tariffs and the Fed: Cramer's 'Mad Money' Recap (Wednesday 10/24/18)

Tariffs and the Fed: Cramer's 'Mad Money' Recap (Wednesday 10/24/18)

This is serious: The market is ignoring legitimate, positive earnings, says Jim Cramer, and tariffs and rates are the culprits.

This Market Needs More Fear: Cramer's 'Mad Money' Recap (Thursday 10/18/18)

This Market Needs More Fear: Cramer's 'Mad Money' Recap (Thursday 10/18/18)

Jim Cramer says there's still too much greed and complacency, and not enough fear and panic.

You Need a Game Plan: Cramer's 'Mad Money' Recap (Friday 10/19/18)

You Need a Game Plan: Cramer's 'Mad Money' Recap (Friday 10/19/18)

Jim Cramer is ready to call the Fed out. And he has your game plan ready for next week.

Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

There is clear divergence between the best and the worst performers in each sector this earnings season.

Stocks to Buy, Stocks to Dump in This Volatile Market

Stocks to Buy, Stocks to Dump in This Volatile Market

Common sense says get more defensive.

Merck's KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared To Standard Of Care, As Monotherapy And In Combination With Chemotherapy, As First-Line Treatment For Patients With Recurrent Or Metastatic Head And Neck Cancer

Merck's KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared To Standard Of Care, As Monotherapy And In Combination With Chemotherapy, As First-Line Treatment For Patients With Recurrent Or Metastatic Head And Neck Cancer

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of interim data from the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, as both monotherapy and in...

European Medicines Agency Adopts Positive Opinion For Merck's KEYTRUDA® (pembrolizumab) As Adjuvant Therapy In Melanoma

European Medicines Agency Adopts Positive Opinion For Merck's KEYTRUDA® (pembrolizumab) As Adjuvant Therapy In Melanoma

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA,...

(Graphic: Business Wire)

(Graphic: Business Wire)

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced detailed results from the Phase 3 SOLO-1 trial testing LYNPARZA 300 mg tablets twice daily as a maintenance treatment for patients with newly-diagnosed...

First Presentation Of Early Data For Merck's Investigational STING Agonist (MK-1454) In Patients With Advanced Solid Tumors Or Lymphomas At ESMO 2018 Congress

First Presentation Of Early Data For Merck's Investigational STING Agonist (MK-1454) In Patients With Advanced Solid Tumors Or Lymphomas At ESMO 2018 Congress

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as...

Merck's KEYTRUDA® (pembrolizumab) Showed A Complete Response Rate Of Nearly 40 Percent In Patients With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive To Standard Of Care

Merck's KEYTRUDA® (pembrolizumab) Showed A Complete Response Rate Of Nearly 40 Percent In Patients With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive To Standard Of Care

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients...

Merck's KEYTRUDA® (pembrolizumab) In Combination With Pfizer's Inlyta® (axitinib) Significantly Improved Overall Survival (OS) And Progression-free Survival (PFS) As First-Line Therapy For Advanced Or Metastatic Renal Cell Carcinoma

Merck's KEYTRUDA® (pembrolizumab) In Combination With Pfizer's Inlyta® (axitinib) Significantly Improved Overall Survival (OS) And Progression-free Survival (PFS) As First-Line Therapy For Advanced Or Metastatic Renal Cell Carcinoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with Inlyta ® (axitinib), Pfizer's...

TheStreet Quant Rating: A+ (Buy)